https://www.pharmaceutical-technology.com/data-insights/avelumab-merck-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/
Avelumab is under clinical development by Merck and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC).
prostate canceravelumabmerckmetastaticcastration
https://www.pharmaceutical-technology.com/data-insights/avelumab-merck-relapsed-acute-myeloid-leukemia-likelihood-of-approval/
Avelumab is under clinical development by Merck and currently in Phase II for Relapsed Acute Myeloid Leukemia.
acute myeloid leukemiaavelumabmerckrelapsedlikelihood